Leukemia drugs in focus at hematology meeting

|By:, SA News Editor

The annual American Society of Hematology meeting is due to start today in New Orleans, where new treatments for chronic lymphocytic leukemia from Gilead Sciences (GILD), Pharmacyclics Inc. (PCYC), Infinity Pharmaceuticals (INFI), Roche (RHHBY) and others will be a focus.

Analysts forecast that the drugs will collectively generate up to $9B a year in annual revenue by 2020.